Alloy Therapeutics announced it has completed an antibody discovery collaboration with Mediar Therapeutics, leveraging its ATX-Gx™ human transgenic mouse platform and AI/ML-enabled workflows to generate high-quality antibody binders against challenging fibrosis targets, significantly accelerating Mediar’s timeline into IND-enabling studies. This effort enables Mediar to advance multiple fibrotic disease programs toward clinical development ahead of schedule and underscores progress in developing novel therapies for fibrotic conditions.
